Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The emerging role of immune checkpoint inhibition in malignant lymphoma
Ida Hude, Stephanie Sasse, Andreas Engert, et al.
Haematologica (2016) Vol. 102, Iss. 1, pp. 30-42
Open Access | Times Cited: 104

Showing 1-25 of 104 citing articles:

The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker
Denis L. Jardim, Aaron M. Goodman, Débora De Melo Gagliato, et al.
Cancer Cell (2020) Vol. 39, Iss. 2, pp. 154-173
Open Access | Times Cited: 808
Combination of fucoidan-based magnetic nanoparticles and immunomodulators enhances tumour-localized immunotherapy
Chih‐Sheng Chiang, Yu‐Jung Lin, Rachel Lee, et al.
Nature Nanotechnology (2018) Vol. 13, Iss. 8, pp. 746-754
Closed Access | Times Cited: 246
Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma
Xin Li, Yasong Cheng, Mingzhi Zhang, et al.
Journal of Hematology & Oncology (2018) Vol. 11, Iss. 1
Open Access | Times Cited: 180
Lactate modulates CD4+ T-cell polarization and induces an immunosuppressive environment, which sustains prostate carcinoma progression via TLR8/miR21 axis
Giuseppina Comito, Anthony Iscaro, Marina Bacci, et al.
Oncogene (2019) Vol. 38, Iss. 19, pp. 3681-3695
Closed Access | Times Cited: 178
Recent Advancements of Magnetic Nanomaterials in Cancer Therapy
Sudip Mukherjee, Lily Liang, Omid Veiseh
Pharmaceutics (2020) Vol. 12, Iss. 2, pp. 147-147
Open Access | Times Cited: 146
Recent developments in immunotherapy of acute myeloid leukemia
Felix S. Lichtenegger, Christina Krupka, Sascha Haubner, et al.
Journal of Hematology & Oncology (2017) Vol. 10, Iss. 1
Open Access | Times Cited: 126
Bruton’s tyrosine kinase (BTK) as a promising target in solid tumors
Javier Molina‐Cerrillo, Teresa Alonso‐Gordoa, Pablo Gajate, et al.
Cancer Treatment Reviews (2017) Vol. 58, pp. 41-50
Closed Access | Times Cited: 118
Toward Biomaterials for Enhancing Immune Checkpoint Blockade Therapy
Qin Fan, Zhipeng Chen, Chao Wang, et al.
Advanced Functional Materials (2018) Vol. 28, Iss. 37
Closed Access | Times Cited: 114
Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies
Pauline Gravelle, Barbara Burroni, Sarah Péricart, et al.
Oncotarget (2017) Vol. 8, Iss. 27, pp. 44960-44975
Open Access | Times Cited: 95
A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure
Amer M. Zeidan, Hanna A. Knaus, Tara M. Robinson, et al.
Clinical Cancer Research (2018) Vol. 24, Iss. 15, pp. 3519-3527
Open Access | Times Cited: 90
Classification of white blood cells using weighted optimized deformable convolutional neural networks
Xufeng Yao, Kai Sun, Xixi Bu, et al.
Artificial Cells Nanomedicine and Biotechnology (2021) Vol. 49, Iss. 1, pp. 147-155
Open Access | Times Cited: 89
Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease
Sung Hee Lim, Jung Yong Hong, Soon Thye Lim, et al.
Annals of Oncology (2017) Vol. 28, Iss. 9, pp. 2199-2205
Open Access | Times Cited: 74
Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research‐practice gaps, challenges, and insights
Ping‐Pin Zheng, Jin Li, Johan M. Kros
Medicinal Research Reviews (2017) Vol. 38, Iss. 1, pp. 325-376
Open Access | Times Cited: 73
Immune checkpoint inhibitor colitis: the flip side of the wonder drugs
Naziheh Assarzadegan, Elizabeth A. Montgomery, Robert A. Anders
Virchows Archiv (2017) Vol. 472, Iss. 1, pp. 125-133
Closed Access | Times Cited: 66
Mechanisms of Immune Evasion and Immune Modulation by Lymphoma Cells
Thomas Menter, Alexandar Tzankov
Frontiers in Oncology (2018) Vol. 8
Open Access | Times Cited: 66
Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment
Manni Wang, Yu Liu, Yuan Cheng, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2019) Vol. 1871, Iss. 2, pp. 199-224
Open Access | Times Cited: 57
Combination Strategies to Augment Immune Check Point Inhibitors Efficacy - Implications for Translational Research
Hrishi Varayathu, Vinu Sarathy, Beulah Elsa Thomas, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 54
iRECIST: how to do it
Thorsten Persigehl, Simon Lennartz, Lawrence H. Schwartz
Cancer Imaging (2020) Vol. 20, Iss. 1
Open Access | Times Cited: 51
A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions
Faroogh Marofi, Heshu Sulaiman Rahman, Muhammad Harun Achmad, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 48
Immune-Checkpoint Inhibitors in B-Cell Lymphoma
Marc Armengol, Juliana C. Santos, Miranda Fernández-Serrano, et al.
Cancers (2021) Vol. 13, Iss. 2, pp. 214-214
Open Access | Times Cited: 42
Novel uses of complement inhibitors in myasthenia gravis—Two case reports
S. Rahman Zadeh, Hayley Price, Reed E. Drews, et al.
Muscle & Nerve (2024) Vol. 69, Iss. 3, pp. 368-372
Closed Access | Times Cited: 7
Boosting γδ T cell-mediated antibody-dependent cellular cytotoxicity by PD-1 blockade in follicular lymphoma
Cédric Rossi, Pauline Gravelle, Emilie Decaup, et al.
OncoImmunology (2018) Vol. 8, Iss. 3, pp. 1554175-1554175
Open Access | Times Cited: 53
PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas
Yi Wang, Ling Wu, Chen Tian, et al.
Annals of Hematology (2017) Vol. 97, Iss. 2, pp. 229-237
Closed Access | Times Cited: 51
Expression and significance of CD47, PD1 and PDL1 in T-cell acute lymphoblastic lymphoma/leukemia
Kun Yang, Jing Xu, Qinghang Liu, et al.
Pathology - Research and Practice (2018) Vol. 215, Iss. 2, pp. 265-271
Open Access | Times Cited: 49
Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy
Nicole A. Carreau, Orrin Pail, Philippe Armand, et al.
The Oncologist (2020) Vol. 25, Iss. 10, pp. 878-885
Open Access | Times Cited: 40
Page 1 - Next Page

Scroll to top